Strategic Partnering Intravacc is a specialized CDMO focused on vaccines and biologics, offering a bridge from discovery to first-in-human trials. This presents a sales opportunity to position complementary manufacturing scale-up services and early-phase support for vaccine developers seeking a reliable transition partner.

Conjugate Vaccine Collaboration Recent partnership with Primrose Bio to enhance development and supply of conjugate vaccines indicates openness to co-development and joint ventures. This suggests potential for joint programs, technology-sharing discussions, and co-funded manufacturing initiatives.

CARB-X Targeting CARB-X funding history in 2024 for gonorrhea vaccine development signals interest in translational vaccine programs addressing antibiotic resistance. Use this to pursue opportunities in infectious disease vaccines requiring clinical translation support and milestone-driven engagements.

Strategic Leadership Changes Executive leadership transitions and board-level changes may create a window for new business development priorities and renewed partnerships. Propose outreach to align with evolving strategic directions and potential emphasis on expanding contract manufacturing capacity.

Global Reputation Being recognized among trusted vaccine manufacturers and operating within Utrecht Science Park positions Intravacc as a credible CDMO for emerging vaccine programs. Target early-stage biotech startups and mid-size companies seeking dependable manufacturing partners with proven vaccine expertise.